Meropenem is an ultra-broad-spectrum injectable antibiotic used to treat a wide variety of infections. It is a β-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Dainippon Sumitomo Pharma. It gained US FDA approval in July 1996. It penetrates well into many tissues and body fluids, including cerebrospinal fluid, bile, heart valve, lung, and peritoneal fluid. It was initially marketed by AstraZeneca under the trade name Merrem.
Mechanism of action
Meropenem is bactericidal except against Listeria monocytogenes, where it is bacteriostatic. It inhibits bacterial wall synthesis like other β-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by β-lactamases or cephalosporinases. In general, resistance arises due to mutations in penicillin-binding proteins, production of metallo-β-lactamases, or resistance to diffusion across the bacterial outer membrane. Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin.
Introduction:
Other name: (4R,5S,6S)-3-[[(3S,5S)-5-Dimethylcarbamoylpyrrolidin-3
CAS NO.: 96036-03-2
MF: C17H25N3O5S
MW: 383.46
Appearance:white or light yellow crystalline powder
Melting point: 117~119.5°C
Density: 1.36 g/cm3
Specification: 78.9%~86.0%
Standard: EP/BP/USP
Odor: odorless
Packaging & Shipping:
Packing:By 25 Kg/Fiber Drum, 1g ,5g ,10g,50g,100g,1kg by plastic bag and aluminum foil bag ,or customized .
Shipping methods: We offer several delivery services to suit all customer needs, such as AIR freight, DHL, FEDEX, TNT, UPS, EMS, SEA freight and others.
CONTACT INFORMATION:
SKYPE:LIVE:BOMIMEDICAL
EMAIL:BOMIMEDICAL@163.COM
Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body
No comments:
Post a Comment